In an interview with leading online biotech site, BioTuesdays, Chief Operating Officer Julian Chick discusses Admedus’ anticipated interim results from a Phase 2 trial of its therapeutic vaccine for the treatment of herpes simplex virus-2 (HSV-2).

Click here to read the full article